An Observational Follow-up Study of Women Who Become Pregnant While Participating in a Certolizumab Pegol (CZP) Clinical Study or Whose Pregnancies Have Otherwise Been Reported to UCB Due to Potential CZP Exposure During Pregnancy
Phase of Trial: Phase IV
Latest Information Update: 06 May 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 23 Nov 2016 Status changed from not yet recruiting to recruiting.
- 09 Nov 2016 Planned initiation date changed from 1 Sep 2016 to 1 Dec 2016.
- 09 Sep 2016 Planned initiation date changed from 1 Aug 2016 to 1 Sep 2016.